fda compounding semaglutide news today 2025 Important Update: Changes to Compounded Availability FDA ends semaglutide shortage, closing

With innovations from Novo Nordisk, Eli Lilly and Company, Amgen, Boehringer Ingelheim, Zealand Pharma, Altimmune and Roche, the pipeline is packed with promising candidates targeting GLP-1 + GIP, glucagon, and amylin

Just weeks after regulators cracked down on these compounded weight loss drugs, the market for cheap alternatives to Ozempic and Eli Lillys Zepbound is bigger than ever, according to Sabina Hemmi, who tracks pricing and providers in the GLP-1 market

2 Is retatrutide more dangerous than Mounjaro or Wegovy

Placement precision matters Not all areas under the tongue are equal

Whether you are managing missed doses or planning for a schedule change, the goal remains the same: maintaining steady levels of the medication to support your metabolic health